These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. Monine M; Norris D; Wang Y; Nestorov I J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294 [TBL] [Abstract][Full Text] [Related]
3. A single-cell map of antisense oligonucleotide activity in the brain. Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501 [TBL] [Abstract][Full Text] [Related]
5. Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System. Chen Y; Mazur C; Luo Y; Sun L; Zhang M; McCampbell A; Tomassy GS J Vis Exp; 2019 Oct; (152):. PubMed ID: 31736489 [TBL] [Abstract][Full Text] [Related]
6. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Barker SJ; Thayer MB; Kim C; Tatarakis D; Simon MJ; Dial R; Nilewski L; Wells RC; Zhou Y; Afetian M; Akkapeddi P; Chappell A; Chew KS; Chow J; Clemens A; Discenza CB; Dugas JC; Dwyer C; Earr T; Ha C; Ho YS; Huynh D; Lozano EI; Jayaraman S; Kwan W; Mahon C; Pizzo M; Robles-Colmenares Y; Roche E; Sanders L; Stergioulis A; Tong R; Tran H; Zuchero Y; Estrada AA; Gadkar K; Koth CMM; Sanchez PE; Thorne RG; Watts RJ; Sandmann T; Kane LA; Rigo F; Dennis MS; Lewcock JW; DeVos SL Sci Transl Med; 2024 Aug; 16(760):eadi2245. PubMed ID: 39141703 [TBL] [Abstract][Full Text] [Related]
7. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides. Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427 [TBL] [Abstract][Full Text] [Related]
8. Direct intraventricular delivery of drugs to the rodent central nervous system. DeVos SL; Miller TM J Vis Exp; 2013 May; (75):e50326. PubMed ID: 23712122 [TBL] [Abstract][Full Text] [Related]
9. Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides. Nishi R; Ohyagi M; Nagata T; Mabuchi Y; Yokota T Mol Ther; 2022 Jun; 30(6):2210-2223. PubMed ID: 35189344 [TBL] [Abstract][Full Text] [Related]
10. Quantitative Model Analysis and Simulation of Pharmacokinetics and Goto A; Yamamoto S; Igari T; Matsumoto SI; Chisaki I; Iida K; Nakayama M; Oda A; Kakoi Y; Uchida A; Miyata K; Nishikawa M; Nagata T; Kusuhara H; Yokota T; Hirabayashi H J Pharmacol Exp Ther; 2023 Jan; 384(1):197-204. PubMed ID: 36273821 [TBL] [Abstract][Full Text] [Related]
11. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks. Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110 [TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. Mohan A; Fitzsimmons B; Zhao HT; Jiang Y; Mazur C; Swayze EE; Kordasiewicz HB Pain; 2018 Jan; 159(1):139-149. PubMed ID: 28976422 [TBL] [Abstract][Full Text] [Related]
13. Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS. Wahlestedt C; Khorkova O Cell Mol Neurobiol; 2021 Jul; 41(5):849-853. PubMed ID: 32656646 [TBL] [Abstract][Full Text] [Related]
14. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Jafar-Nejad P; Powers B; Soriano A; Zhao H; Norris DA; Matson J; DeBrosse-Serra B; Watson J; Narayanan P; Chun SJ; Mazur C; Kordasiewicz H; Swayze EE; Rigo F Nucleic Acids Res; 2021 Jan; 49(2):657-673. PubMed ID: 33367834 [TBL] [Abstract][Full Text] [Related]
15. DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs. Ohara M; Nagata T; Hara RI; Yoshida-Tanaka K; Toide N; Takagi K; Sato K; Takenaka T; Nakakariya M; Miyata K; Maeda Y; Toh K; Wada T; Yokota T Mol Ther Nucleic Acids; 2024 Sep; 35(3):102289. PubMed ID: 39252874 [TBL] [Abstract][Full Text] [Related]
16. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier. Min HS; Kim HJ; Naito M; Ogura S; Toh K; Hayashi K; Kim BS; Fukushima S; Anraku Y; Miyata K; Kataoka K Angew Chem Int Ed Engl; 2020 May; 59(21):8173-8180. PubMed ID: 31995252 [TBL] [Abstract][Full Text] [Related]
17. Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System. Kennedy Z; Gilbert JW; Godinho BMDC Methods Mol Biol; 2022; 2434():345-353. PubMed ID: 35213030 [TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. Kim TW; Kim KS; Seo JW; Park SY; Henry SP J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663 [TBL] [Abstract][Full Text] [Related]